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Background: Acute myeloid leukemia (AML) is the second most common form of leukemia in children. Aberrant
DNA methylation patterns are a characteristic feature in various tumors, including AML. Metallothionein III (MT3) is a
tumor suppresser reported to show promoter hypermethylated in various cancers. However, the expression and
molecular function of MT3 in pediatric AML is unclear.
Methods: Eleven human leukemia cell lines and 41 pediatric AML samples and 20 NBM/ITP (Norma bone marrow/
Idiopathic thrombocytopenic purpura) control samples were analyzed. Transcription levels of MT3 were evaluated
by semi-quantitative and real-time PCR. MT3 methylation status was determined by methylation specific PCR (MSP)
and bisulfite genomic sequencing (BSG). The molecular mechanism of MT3 was investigated by apoptosis assays
and PCR array analysis.
Results: The MT3 promoter was hypermethylated in leukemia cell lines. More CpG’s methylated of MT3 was
observed 39.0% pediatric AML samples compared to 10.0% NBM controls. Transcription of MT3 was also
significantly decreased in AML samples compared to NBM/ITP controls (P < 0.001); patients with methylated MT3
exhibited lower levels of MT3 expression compared to those with unmethylated MT3 (P = 0.049). After transfection
with MT3 lentivirus, proliferation was significantly inhibited in AML cells in a dose-dependent manner (P < 0.05).
Annexin V assay showed that apoptosis was significantly upregulated MT3-overexpressing AML cells compared to
controls. Real-time PCR array analysis revealed 34 dysregulated genes that may be implicated in MT3 overexpression
and apoptosis in AML, including FOXO1.
Conclusion: MT3 may be a putative tumor suppressor gene in pediatric AML. Epigenetic inactivation of MT3 via
promoter hypermethylation was observed in both AML cell lines and pediatric AML samples. Overexpression of
MT3 may inhibit proliferation and induce apoptosis in AML cells. FOXO1 was dysregulated in MT3-overexpressing
cells, offering an insight into the mechanism of MT3-induced apoptosis. However, further research is required to
determine the underlying molecular details.
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Acute myeloid leukemia (AML) is a type of cancer in the
myeloid cell. It is the most common form of acute leukemia
in adults and the second most common form of leukemia
in children after acute lymphoblastic leukemia (ALL) [1,2].
The incidence of AML increases with age and is character-
ized by the rapid growth of abnormal white blood cells
which accumulate in the bone marrow and interfere with
the production of normal blood cells [3].
DNA methylation is an important regulator of gene
transcription. It is an epigenetic modification that typic-
ally occurs at CpG (cytosine-phosphate-guanine) sites in
mamalian cells. It is catalyzed by DNA methyltrans-
ferase which results in the conversion of the cytosine
residue to 5-methylcytosine, leading to the formation of
Me-CpG [4]. Alterations in DNA methylation fre-
quently occur during cell development and are common
in tumors. Aberrant DNA methylation patterns have been
reported in a variety of cancers including AML [5,6].
Hypermethylation within the promoter regions of tumor
suppressor genes leads to gene silencing, and global
hypomethylation has also been recognized as a cause
of oncogenesis [7,8]. As such, the role of methylation
in carcinogenesis has been the focus of considerable
research. However, the mechanisms leading to aber-
rant DNA methylation are poorly understood.
Genome-wide studies have been performed to obtain
details on the genome and epigenome in various solid
tumors. Examination of clonal evolution patterns have
suggested that these may shape epigenetic dysregulation
in AML. Investigations on genome-wide methylation in
AML have shown variations in methylation patterns be-
tween AML and normal healthy tissues [9-11]. Although
several studies have found that molecular subtypes in
AML can exhibit highly distinct DNA methylation pro-
files [12,13], a small set of common genes have also been
shown to exhibit consistent aberrant methylation across
several hundred cases of AML [14,15], such as PML-RARα
and AML1-ETO [12,13,16]. Together, these findings impli-
cate distinct aberrant DNA methylation patterns in the
pathogenetic processes in cancer, rather than evolving
homogeneously across cancer types,
Deep sequencing of patients with different myeloid ma-
lignancies has revealed recurrent mutations in epigenetic
regulator proteins, such as DNMT3A and TET2, and
several major driver mutations in normal karyotype AML
[17,18]. Functional studies of these mutations have re-
vealed specific methylation signatures. These mutations
carry prognostic relevance and are likely to be contribu-
tors to AML pathogenesis.
Metallothionein (MT) is a family of cysteine-rich, low
molecular weight (500–14,000 Da) proteins [19]. Ten
functional isoforms of MTs have been identified, which
are divided into four classes (MT1–4) based on smalldifferences in protein sequences and characteristics. MTs
have been proposed to play important roles in protecting
against DNA damage, apoptosis and oxidative stress. MT3
was first identified as a neuronal growth inhibitory factor
[20]. In vitro studies have demonstrated that MT3 can in-
hibit neurite formation and survival in neurons [20]. It has
been shown to protect against apoptotic neuronal death
in the brains of patients with Alzheimer’s disease and
in the hippocampus of SAMP8 mice, suggesting that
MT3 may inhibit the development of neurodegeneration
and may influence neuronal regeneration during the re-
covery process [21,22]. Its endogenous overexpression in
glial and tumor cells stably transfected with MT3 was
found to inhibit cell growth. In addition, MT3 plays a role
in regulating lysosomal functions; in the absence of MT3,
reductions in specific lysosomal enzymes associated with
decreased autophagic flux have been reported [23].
In relation to cancer, downregulation of MT3 has been
reported as one of 17 changes in gene expression which
are associated with metastasis and poor clinical outcome
in a range of solid tumors, including gastric cancer [24]
and primary esophageal squamous cell carcinoma (SCC)
[25]. This was supported by the observation that treat-
ment with 5-aza-2'-deoxycytidine, an inhibitor of DNA
methylation reduced the degree of methylation and in-
crease the level of MT3 expression, in esophageal SCC
cell lines [25]. Significant downregulation of MT3 has
been most frequently reported in tumors that exhibiting
MT3 methylation, suggesting that MT3 may act as a
tumor suppresser via promoter hypermethylation [26].
However, reports on the methylation status of MT3 in
the blood system are rare, and its expression and role in
pediatric AML remains unclear. The aim of this study
was to analyze the methylation profile and molecular
function of MT3 in pediatric AML.
Methods
Cell lines
Leukemia cell lines HL-60, MV4-11, U937, DAMI and
K562 were obtained from the American Type Culture
Collection (ATCC). CCRF, Raji, Jurkat, 697 and SHI-1
cell lines (gifts from Professor Wang Jian-Rong, The Cyrus
Tang Hematology center of Soochow University). All cell
lines were maintained at 37°C in the RPMI 1640 (GibcoR,
Life Technologies, Carlsbad, CA) supplemented with
10% fetal bovine serum (Invitrogen, Life Technologies,
Carlsbad, CA).
Patients and samples
Bone marrow specimens were obtained at the time of diag-
nosis during routine clinical assessment of 41 pediatric
patients with AML, who presented at the Department
of Hematology and Oncology, Children’s Hospital of
Soochow University between 2000 and 2010. Ethical
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Soochow University Ethics Committee (No. SUEC2000-
021), and informed consent was obtained from the parents
or guardians. AML diagnosis was made in accordance
with the revised French–American–British (FAB) classifi-
cation. The main clinical and laboratory features of the
patient cohort are summarized in Table 1. Addition-
ally, bone marrow samples from 12 healthy donors and
8 patients with Idiopathic thrombocytopenic purpura
(ITP) were analyzed as controls. Bone marrow mono-
nuclear cells (BMNCs) were isolated using Ficoll solution
within 2 h after bone marrow samples harvested and im-
mediately subjected for the extraction of total RNA and
genomic DNA.
CD34 + cell purification
For CD34 +cell selection, the Miltenyi immunoaffinity
device (VarioMACS 130-046-703) was used according
to the manufacturer’s instructions (Miltenyi Biotech,
Auburn, CA). Briefly, the CD34+ cells are magnetically la-
beled with CD34 MicroBeads. Then, the cell suspension is
loaded onto a MACSR Column which is placed in the
magnetic field of a MACS Separator. The magnetically la-
beled CD34+ cells are retained within the column. The
unlabeled cells run through; CD34+ cells were adsorbed
on the magnetic poles. After removing the column from
the magnetic field, the magnetically retained CD34+ cells
can be eluted as the positively selected cell fraction.
Sodium bisulfite modification of genomic DNA
High-molecular-weight genomic DNA was extracted from
cell lines and biopsies by a conventional phenol/chloroform
method. The sodium bisulphite modification procedure
was as described [27] with slight modification. In brief,
600 ng of genomic DNA was denatured in 3 M NaOH forTable 1 Correlation between MT3 methylation status and clin
Clinical and pathologic features
Methylated (n = 16)
Age (years) 5.17 (1–13)
Gender (male/female ratio) 10/6
WBC: median; range (109/L) 14.1 (0.8–51.1)
Hemoglobin: median; range (g/L) 70.1 (32–176)
Platelet count: median; range (109/L) 57.2 (12–310)







FAB, French-American-British; WBC, White blood cells. *P < 0.05.15 min at 37°C, then mixed with 2 volumes of 2% low-
melting-point agarose. Agarose/DNA mixtures were then
pipetted into chilled mineral oil to form agarose beads. Al-
iquots of 200 μl of 5 M bisulphite solution (2.5 M sodium
metabisulphite, 100 mM hydroquinone, both Sigma, USA)
were added into each tube containing a single bead. The
bisulphite reaction was then carried out by incubating the
reaction mixture for 4 h at 50°C in the dark. Treatments
were stopped by equilibration against 1 ml of TE buffer,
followed by desulphonation in 500 μl of 0.2 M NaOH. Fi-
nally, the beads were washed with 1 ml of TE buffer and
directly used for PCR.
Methylation-specific PCR
The methylation status of the MT-3 promoter region
was determined by methylation-specific PCR. Primers
distinguishing unmethylated (U) and methylated (M) al-
leles were designed to amplify the sequence:
MT-3 M-forward: 5- TTAAGCGTATAAACGGAAA
GAGC −3;
MT-3 M-reverse: 5- AAAACAAATCTCAAAATCCA
TATCG −3;
MT-3 U-forward: 5- TTTAAGTGTATAAATGGAAA
GAGTGG −3;
MT-3 U-reverse: 5- AACAAATCTCAAAATCCATAT
CAAA −3.
Each PCR reaction contained 20 ng of sodium bisulphite-
modified DNA, 250 pmol of each primer, 250 pmol deoxy-
nucleoside triphosphate, 1 × PCR buffer, and one unit of
ExTaq HS polymerase (Takara, Tokyo) in a final reaction
volume of 20 μl. Cycling conditions were initial denatur-
ation at 95°C for 3 min, 40 cycles of 94°C for 30 s, 60°C
(M) or 58°C (U) for 30 s, and 72°C for 30 s. For each set oficopathological features in pediatric AML patients
Median (range)
Unmethylated (n = 25) Total patients (n = 41) P-value
6.72 (1–11) 6.16 (1–13) 0.622
11/14 21/20
18.2 (0.8–43.6) 16.6 (0.8–51.1) 0.757
75.2 (32–107) 73.2 (32–176) 0.812
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genomic DNA treated with sodium bisulphite served as a
positive methylation control. PCR products were sepa-
rated on 4% agarose gels, stained with ethidium bromide
and visualized under UV illumination. For cases with bor-
derline results, PCR analyses were repeated.
Bisulfite genomic sequencing
Bisulfite genomic sequencing (BGS) was performed as pre-
viously described [28]. BGS primers were from +427 to
+672 including 15 CpGs. MT-3 F: 5- AGGGAGATTTGG
TATTTTATTTTTT-3 and MT-3 R: 5- ACCTAACTA
TCTCTCCACATCCTAC-3. Amplified BGS products
were TA-cloned; and five to six randomly chosen colonies
were sequenced. DNA sequences were analyzed with
QUMA Analyzer. (http://quma.cdb.riken.jp/).
Leukemia cell cells treated with 5-aza-2'-deoxycytidine
De-methylation was induced with 5-aza-dC (5-Aza, Sigma-
Aldrich, St Louis, MO, USA) treatment at a concen-
tration that induced de-methylation of the DNA without
killing the cells. Culture media for HL-60 and MV4-11
cells contained 5 μM 5-Aza. DNA and RNA were ex-
tracted after 72 hours of 5-Aza treatment for the following
analysis.
Quantitative reverse-transcription PCR for MT-3
Quantitative real-time PCR was performed to determine
the expression levels of MT-3 genes. Total RNA was re-
verse transcribed using the Reverse Transcription Kit,
according to the manufacturer’s protocol (Applied Biosys-
tems Inc., Foster City, CA). The real time PCR primers
used to quantify GAPDH expression were: F: 5′-AGAAG
GCTGGGGCTCATTTG-3′ and R: 5′-AGGGGCCATC
CACAGTCTTC-3′ and for MT-3 were: F: 5′-ACACA
CAGTCCTTGGCACAC-3′ and R: 5′-AAGTGCGAGG
GATGCAAAT-3′. Expression of MT-3 was normalized to
endogenous GAPDH expression.
MT-3 lentiviral expression constructs and lentivirus
production
Briefly, an approximately 250 bp fragment containing
the human MT-3 gene was directly synthesized, and
cloned into the pMD18-T vector. Positive clones were
confirmed by sequencing and subcloned into the pLVX-
IRES-ZsGreen vector (Clontech). The vector plasmids,
pLVX-IRES-ZsGreen1, pLP1, pLP2 and pLP/VSVG were
amplified in E.Coli and purified using the Endofree Max-
iprep Kit (Qiagen). 270 μg of transfer vector, 176 μg of
pLP1, 95 μg of pLP/VSVG and 68 μg of pLP2 was mixed
with 0.25 M CaCl2 (Sigma) and added to same volume
of 2 × HEPES (Sigma) and mixed while bubbling for
20 min to allow a precipitate to form. This was then added
to a 175 cm2 flask of approximately 60% confluent 293 Tcells containing 20 mL DMEM supplemented with 10%
fetal calf serum, 100 U/mL penicillin, 100 μg/mL strepto-
mycin and 2 mM glutamine and incubated for 48 h at
37°C in 5% CO2. The supernatant was centrifuged at
1,700 g for 10 min to pellet cell debris, and ultracen-
trifuged at 121,603 g for 2 h. The pellet containing con-
centrated virus was resuspended in DMEM without
supplements and stored at -80°C.Cell proliferation analysis
Acute myeloid leukemia cells were seeded in 96-well plates
at 2 × 104 cells per well. 20 ul CCK-8(Dojindo Molecular
Technologies, Japan) was added to each well and incubated
at 37°C for a further 4 hours. The optical density (OD)
values were measured at 450 nm on a scanning multi-well
spectrophotometer (BioRad Model 550, USA). Compared
with the control group, Cell proliferation was calculated
as proliferation values. All experiments were performed
in triplicate and repeated twice. The results were analyzed
using ANOVA and the Student-Newman-Keuls tests,
p < 0.05 were considered significant.Apoptosis assay
Apoptosis assay was according to the manual operation
of BD Annexin V Staining Kit (Cat: 556420, BD Biosci-
ences, Franklin Lakes and NJ USA). Briefly, wash cells
twice with cold PBS and then resuspend cells in 1 ×
Binding Buffer at a concentration of ~1 × 106 cells/ml.
Transfer 100 μl of the solution (~1 × 105 cells) to a 5 ml
culture tube. Add Annexin V and PI 5 μl/test. Gently
mix the cells and incubate for 15 min at RT in the dark.
Add 400 μl of 1 × Binding Buffer to each tube. Analyze
by flow cytometry as soon as possible (within 1 hour).Western blot analysis
For western blot analysis, cellular proteins were extracted
in 40 mM Tris–HCl (pH 7.4) containing 150 mM NaCl
and 1% (v/v) Triton X-100, supplemented with a cocktail
of protease inhibitors. Equal amounts of protein were re-
solved on 12% SDS-PAGE gels, and then transferred to a
PVDF membrane (Millipore, Bedford, MA). Blots were
blocked and then probed with antibodies against MT-3
(1:1000, Abcam, Cambridge, MA Office, USA), PARP
(1:1000, Cell Signaling Technology, Inc. Danvers, MA),
FOXO1 (1:1000, Cell Signaling Technology, Inc. Danvers,
MA), CDKN1A (1:1000, Cell Signaling Technology, Inc.
Danvers, MA), GAPDH (1:5000, Sigma, St. Louis, MO).
After washing, the blots were incubated with horseradish
peroxidase-conjugated secondary antibodies and visualized
by enhanced chemiluminescence kit (Pierce, Rockford, IL).
Protein bands were visualized after exposure of the mem-
brane to Kodak X-ray film.
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For RNA extraction, cells were immediately submerged
in 2 ml Trizol (Invitrogen Co., NY, USA), stored at −80°C
until further processed. A volume of 1 ml of each sample
was spun at 4°C for 15 min at 12,000 g to remove debris
and DNA, 1 ml of supernatant was mixed with 200 ul
chloroform, shaken for 15 seconds, incubated at Room
Temperature for 2–3 minutes and spun for 10 minutes
at 12,000 g at 4°C. RNA was precipitated by adding
500 ul of the aqueous phase to an equal volume of
isopropanol and spun at 14,000 g at 4°C for 10 minutes.
RNA was washed with 75% ethanol, spun at 14,000 g at
4°C for 10 minutes, dried and resuspended in 40 ul
DEPC-treated H2O. The final RNA concentration was
determined using a spectrophotometer (Nanodrop 2000)
and the purity was assessed by agarose gel electrophor-
esis. cDNA synthesis was performed on 4 ug of RNA
in a 10 ul sample volume using SuperScript II reverse
transcriptase (Invitrogen Co., NY, USA) as recom-
mended by the manufacturer. The RNA was incu-
bated with 0.5 ug of oligo (dT)12–18mers primers
(Invitrogen Co., NY, USA) for 7 minutes at 70°C and
then transferred onto ice. Then, 9 ul of a master mix
containing 4 ul of SuperScript II buffer, 2 ul of 0.1 M
DTT, and 1 ul each of dNTPs stock (10 mM), Rnasin
(40 UI) and SuperScript II were added to the RNA
sample, spun and incubated at 42°C for 60 min followed
by 5 min at 70°C to inactivate the enzyme. cDNA was
stored at −20°C. Real-time PCR array (SABioscience
Human Apoptosis PCR Array PAHS-3012) analysis
was performed in a total volume of 20 ul including
2ul of cDNA, primers (0.2 mM each) and 10 ul of
SYBR Green mix (Roche Co., Basel, Switzerland). Re-
actions were run on an Light cycler 480 using the
universal thermal cycling parameters (95°C 5 min,
45 cycles of 10 sec at 95°C, 20 sec at 60°C and 15 sec at
72°C; melting curve: 10 sec at 95°C, 60 sec at 60°C
and continues melting). Results were obtained using
the sequence detection software Light cycler 480 and
analyzed using Microsoft Excel. For all samples melt-
ing curves were acquired for quality control purposes.
For gene expression quantification, we used the com-
parative Ct method. First, gene expression levels for
each sample were normalized to the expression level
of the housekeeping gene encoding Glyceraldehydes
3-phosphate dehydrogenase (GAPDH) within a given
sample (−⊿Ct); the relative expression of each gene
was calculated with 105 *Log2(−⊿Ct). The difference
between the MT-3 over-expression samples compared
to the control samples was used to determine the 106
*Log2(−⊿Ct). Statistical significance of the gene ex-
pression difference between the MT-3 over-expression
and the control samples was calculated with the T-
test using SPSS 11.5 software.Statistical analysis
SPSS v11.5 (SPSS Inc., Chicago, IL) was used for statis-
tical analysis. Data are presented as means ± standard
deviation. Group t-test was used to compare the expres-
sion of MT-3 between DMSO group and 5-Aza group.
Statistical significance between methylated sample data
and clinical pathological features of AML patients were
analyzed by Pearson chi-square test or Fisher’s exact test.
Statistical significance of MT-3 expression among NBM
and pediatric AML groups was determined using one-
way ANOVA. A p < 0.05 was considered statistically
significant.
Results
The MT3 promoter is hypermethylated in AML cells
Our long-term research is focused on epigenic modifica-
tion in pediatric AML and we have found a series of ab-
normal methylated genes related with AML [29,30]. In
this study we conducted CpG island array analysis to ex-
plore promoter methylation in pediatric AML. The hyper-
methylated and hypomethylated genes between AML
and NBM were clustered in Figure 1 and Additional
file 1. The results implied that the MT3 promoter was
hypermethylated in AML. Subsequent analyses identified
four CpG islands in the MT3 promoter region (Figure 2A).
Therefore, we conducted an MSP assay in 11 leukemia
cell lines using a primer for MSP analysis that encom-
passed the CpG islands in the MT3 promoter. Our results
showed that the MT3 promoter was hypermethylated
in 7/11 leukemia cell lines, with the highest methyla-
tion levels observed in HL-60, MV4-11 SHI-1, U937
and K562 cells; whereas it was unmethylated in 4/11 cell
lines, 697, SHI-1, THP-1 and Jurkat (Figure 2B). To con-
firm methylation of the MT3 promoter, we treated the
leukemia cell lines with 5-Aza. This demethylation re-
agent is an epigenetic modifier that inhibits DNA
methyltransferase activity resulting in hypomethylation
and gene activation. PCR analysis showed that methy-
lation status of MT3 was decreased in leukemia cells
following 5-Aza treatment compared to control cells
treated with DMSO. Our results showed that MT3
expression was significantly upregulated in leukemia
cells following 5-Aza treatment compared to control
cells treated with DMSO (Figure 2C): MT3 expression
was upregulated 39.8 fold in HL-60 cells (24.27 vs.
0.61, respectively; P = 0.013); and 26.8 fold in MV4-11
cells (34.27 vs. 1.28, respectively; P = 0.006).
The MT3 promoter was methylated in patients with
pediatric AML
In order to examine the methylation status in the MT3
promoter in pediatric AML, we obtained samples from 41
patients with pediatric AML and 20 control patients with
NBM/ITP. Aberrant MT3 methylation was observed in
Figure 1 Analysis of promoter methylation in pediatric AML by NimbleGen Human DNA Methylation arrays. Analysis of the methylation
status of genes in five pediatric AML samples (L1, L2, L3, L4 and L5) and three NBM samples (N1, N2, and N3) using NimbleGen Human DNA
Methylation arrays shows that the MT3 promoter is significantly methylated in AML samples (5/5) and unmethylated in NBM samples (1/3).
(A) Each red box represents the number of methylation peaks (PeakScore) overlapping the promoter region for the corresponding gene.
The PeakScore is defined as the average -log10 (P-value) from probes within the peak. (B) The scores reflect the probability of positive
methylation enrichment.
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Figure 2 The MT3 promoter is methylated in AML cell lines. (A) Four CpG island regions can be identified in the promoter of MT3. (B) MSP
analysis of the methylation status of MT3 in leukemia cell lines shows that the promoter is hypermethylated in 7/11 cell lines. M and U represent
MSP results using primer sets for methylated and unmethylated MT3 genes, respectively. (C) PCR analysis showed that methylation status of MT3
was decreased in leukemia cells following 5-Aza treatment compared to control cells treated with DMSO. The transcript level of MT3 is significantly
upregulated in HL-60 cells and MV4-11cells treated with 5-Aza compared to those treated with DMSO. *P < 0.05; **P < 0.01.
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10.0% (2/20) of the NBM control samp (Figure 3A). Six
NBM samples and six AML samples were selected for fur-
ther analysis by BGS (Figure 3B). Consistent with the
MSP results, these confirmed that the CpG islands in theMT3 promoter were methylated in the AML samples
(68%-86.7%); whereas they were unmethylated in the
NBM samples (49.3%-61.3%).
Examination of the clinicopathologic characteristics in pa-
tients with pediatric AML revealed that there were no
Figure 3 MT3 is inactivated by promoter hypermethylation in AML cell lines. (A) MSP analysis of the methylation status of MT3 shows
aberrant methylation in pediatric AML samples compared to NBM/ITP control samples. Aberrant methylation of MT3 was observed in 39.0%
(16/41) of the pediatric AML samples compared to 10.0% (2/20) of the NBM control samples. M and U represent MSP results using primer sets for
methylated and unmethylated MT3 genes, respectively. (B) BGS results of three AML samples and three NBM samples show that CpG islands are
methylated in the AML samples and unmethylated in the NBM control samples. (C) Real-time PCR analysis of the transcript levels of MT3 in 41
pediatric AML samples and 20 NBM control samples. (D) Quantification shows that MT3 expression is significantly decreased in the AML samples
compared to the NBM/ITP control samples. Furthermore, AML patients with methylated MT3 (n = 16) show lower MT3 transcript levels than those
unmethylated MT3 (n = 25).
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Figure 4 Overexpression of MT3 inhibited proliferation an induced apoptosis in leukemia cells. (A) Transfection with MT3 lentivirus
PLVX-MT3 significantly upregulates expression of MT3 in AML cells compared to mock transfected cells. (B) CCK-8 assays show that transfection
with MT3 lentivirus inhibits proliferation in HL-60 and MV4-11 cells in a dose-dependent manner compared to mock transfected cells. (C) The
number of cells displaying apoptotic features is higher in the HL-60 an MV4-11 cells transfected with PLVX-MT3compared to the mock transfected
cells. (D) Quantification shows that the percentage of apoptotic cells in PLVX-MT3 transfected group is significantly higher compared to the
percentage in the mock control group. *P < 0.05; **P < 0.01.
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Figure 5 Real-time PCR array analysis showing dysregulated genes implicated in MT3 overexpression. (A) In order to identify genes
associated with MT3 overexpression and apoptosis in AML cells, we analyzed and clustered the expressions of 370 key genes involved in apoptosis using the
SABioscience Human Apoptosis PCR Array PAHS-3012 kit. (B) Relative expression of the genes most downregulated in MT3-overexpressing AML cells
compared to mock transfected cells. (C) Relative expression of the genes most upregulated in MT3-overexpressing cells compared to mock transfected cells.
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initial hemoglobin level, white blood cell counts, platelet
counts and chromosomal abnormalities between those
with methylated MT3 and those with unmethylated MT3
(Table 1).Real-time qPCR was employed to examine the tran-
script levels of MT3 in the 41 pediatric AML samples
and 20 NBM/ITP control samples (Figure 3C; Table 1).
MT3 expression was found to be significantly decreased
in the AML samples compared to the control samples
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lysis of the AML samples showed that 16/41 patients with
pediatric AML displayed methylated MT3 compared to 25/
41 patients with unmethylated MT3 (Table 1). Further-
more, those with methylated MT3 showed significantly
lower levels of MT3 expression compared to those
with unmethylated MT3 (10.65 ± 10.19 vs. 19.23 ± 16.93; P
= 0.049; Figure 3D). In summary the hypermethylation sta-
tus of the MT3 promoter in samples from patients
with pediatric AML was consistent with results in human
myeloid leukemia cell lines.
Overexpression of MT3 inhibited proliferation and
induced apoptosis in leukemia cells
Transfection of the PLVX-MT3 lentivirus into HL-60
and MV4-11 leukemia cells was found to significantly
upregulate expression of MT3 (Figure 4A) and signifi-
cantly inhibit cell proliferation (Figure 4B). A CCK-8
assay in HL-60 and MV4-11cells showed that the inhib-
ition rate at 5 days post-transfection was 43.7 ± 30.1%
and 51.1 ± 26.8% in MT3-overexpessing cells compared
to the mock transfection group (P < 0.05).
To determine whether MT3 induced apoptosis in
leukemia cells, we performed an Annexin V assay in HL-
60 and MV4-11 leukemia cells following transfection
(Figure 4C and D). The results showed that the propor-
tion of apoptotic cells in the MT3-overexpressing cells
(PLVX-MT3) was significantly greater than that in the
control group (PLVX-Ve): HL-60 (8.40% ± 1.04% vs. 0.5% ±Table 2 Genes up regulated in HL-60 cells treated with PLVX-
Gene Description
1 FOXO1 forkhead box O1
2 IER3 immediate early response 3
3 CD5 CD5 molecule
4 NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3
5 TNFAIP3 tumor necrosis factor, alpha-induced protein 3
6 TNF tumor necrosis factor
7 DDIT3 DNA-damage-inducible transcript 3
8 CRADD CASP2 and RIPK1 domain containing adaptor with de
9 BNIP1 BCL2/adenovirus E1B 19 kDa interacting protein 1
10 BBC3 BCL2 binding component 3
11 NOX5 NADPH oxidase, EF-hand calcium binding domain 5
12 CASP7 caspase 7, apoptosis-related cysteine peptidase
13 PIM2 pim-2 oncogene
14 CEBPG CCAAT/enhancer binding protein (C/EBP), gamma
15 EDA ectodysplasin A
16 SOCS2 suppressor of cytokine signaling 2
17 CDKN1A cyclin-dependent kinase inhibitor 1A0.3%, respectively; P = 0.003); and MV4-11 (7.53% ± 1.49%
vs. 0.73 ± 0.21%, respectively; P = 0.014).
To further investigate the apoptotic effect of MT3 in
HL-60 and MV4-11 cells, we investigated the expression
levels of cleaved PARP, a marker of apoptosis, by Western
blotting. The results were consistent with the Annexin V
data, confirming that MT3 induced apoptosis in leukemia
cells (Figure 4A).
Dysregulation of apoptosis-related genes in HL-60 cells
overexpressing MT3
In order to identify the apoptosis-related genes impli-
cated in MT3 overexpression in HL-60 cells, we ana-
lyzed expression and clustering of 370 key genes
associated with apoptosis by real-time PCR array ana-
lysis, cells harboring empty vector or a vector overex-
pressing MT3 were subjected to real-time PCR array
(Figure 5A). The genes most significantly downregu-
lated or upregulated are shown in Figures 5B and
5C, respectively. Examination of the array data re-
vealed that 17 genes were significantly upregulated
and 17 genes were significantly downregulated in
the MT3-overexpressing group compared to the con-
trol group (Tables 2 and 3, respectively). These in-
cluded TNF (tumor necrosis factor) ligands and their
receptors, members of the bcl-2 family, BIRC (baculo-
viral IAP repeat) domain proteins, CARD (caspase re-
cruitment domain) proteins, death domain proteins,
TRAF (TNF receptor-associated factor) domainMT-3 compared with control group
Control MT-3 FC P
26.4281 331.0229 12.5254 0.010474
452.3756 4374.4713 9.6700 0.010816
0.6702 6.2407 9.3121 0.010872
1081.0850 9828.4023 9.0912 0.010909
587.6202 4806.8271 8.1802 0.011077
0.4428 3.4995 7.9040 0.011134
1145.0392 8216.9381 7.1761 0.011304
ath domain 86.0764 598.6941 6.9554 0.011361
763.0465 5084.0947 6.6629 0.011443
11.7979 73.7195 6.2486 0.01157
1.8139 11.2984 6.2286 0.011576
172.3255 1016.9670 5.9014 0.011688
247.2885 1270.8713 5.1392 0.012
100.8660 510.3751 5.0599 0.012038
6.0342 30.4256 5.0422 0.012047
2.1896 10.8844 4.9710 0.012082
1057.6600 5124.4420 4.8451 0.012147
Table 3 Genes down regulated in HL-60 cells treated with PLVX-MT-3 compared with control group
Gene Description Control MT-3 FC P
1 CUL3 cullin 3 10.4408 0.6273 0.0601 0.008493
2 MAPK8IP2 mitogen-activated protein kinase 8 interacting protein 2 3.6692 0.5249 0.1431 0.009149
3 NTF3 neurotrophin 3 2.5110 0.4725 0.1882 0.009344
4 CCL2 chemokine (C-C motif) ligand 2 88.1973 18.1459 0.2057 0.009402
5 HSPA1B heat shock 70 kDa protein 1B 9152.4687 2147.2853 0.2346 0.00949
6 PRKCA protein kinase C, alpha 259.7601 68.8275 0.2650 0.009593
7 ALOX15B arachidonate 15-lipoxygenase, type B 2.2320 0.6779 0.3037 0.009776
8 SST somatostatin 5.9015 1.9173 0.3249 0.009921
9 SEMA4D sema domain, immunoglobulin domain 4D 82.5241 27.6746 0.3354 0.010009
10 CARD18 caspase recruitment domain family, member 18 6.4031 2.1791 0.3403 0.010055
11 NAIP NLR family, apoptosis inhibitory protein 374.1656 136.0874 0.3637 0.010316
12 FADD Fas (TNFRSF6)-associated via death domain 2746.1986 1001.6552 0.3647 0.010329
13 FAIM2 Fas apoptotic inhibitory molecule 2 34.8320 13.2906 0.3816 0.010573
14 CARD9 caspase recruitment domain family, member 9 44.1602 16.8715 0.3821 0.01058
15 ALOX12 arachidonate 12-lipoxygenase 82.6640 32.4829 0.3930 0.010768
16 CARD8 caspase recruitment domain family, member 8 32.5951 12.9265 0.3966 0.010835
17 CASP10 caspase 10, apoptosis-related cysteine peptidase 114.4506 45.4485 0.3971 0.010845
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most upregulated gene in MT3-overexpressing group.
The up-regulation of FOXO1 and CDKN1A in MT3-
overexpressing group was vivificated with western-blot
analysis (Figure 6).
Discussion
In this study, we found that the MT3 promoter was
hypermethylated in pediatric AML. Our results showed
that the MT3 promoter was hypermethylated in seven outFigure 6 Western-blot analysis showing up-regulation of
FOXO1 and CDKN1A implicated in MT3-overexpressing.
Western-blot analysis showed that expression of CDKN1A and
FOXO1 is significantly up-regulated in MT3-overexpressing cells
compared to mock transfected cells.of eleven human myeloid leukemia cell lines. Furthermore,
in agreement with reports in esophageal SCC, treatment
with 5-Aza, a specific inhibitor of DNA methylation, led
to a significant increase in MT3 expression in AML cells
(39.8 fold in HL-60 and 26.8 fold in MV4-11; P < 0.05 and
P < 0.01, respectively). These results demonstrated that
the MT3 promoter was consistently significantly methyl-
ated in human myeloid leukemia cells, suggesting that the
MT3 promoter may also be methylated in pediatric AML.
Consistent with the cell line results, we found that the
MT3 promoter was methylated in samples obtained from
patients with pediatric AML. Aberrant methylation of
MT3 was observed 39.0% (16/41) of pediatric AML sam-
ples compared to 6.7% (2/30) of NBM control samples. In
addition, MT3 was significantly downregulated in the
pediatric AML samples compared to the control samples.
Further analysis revealed that patients with pediatric AML
exhibiting methylated MT3 showed lower levels of MT3
expression compared to those with unmethylated MT3.
These results confirmed that hypermethylation of the
MT3 promoter occurs with high frequency in both AML
cell lines and pediatric AML samples. However, com-
parisons between the two groups of patients showed no
significant differences in MT3 methylation status and
patient characteristics, including sex, age, initial hemoglobin
level, white blood cell counts, platelet counts, and
chromosomal abnormalities. Together, these results im-
plied that various mechanisms may be involved in the
downregulation of MT3 in pediatric AML, such as differ-
ent post-transcriptional modifications, gene deletions,
copy number reductions and histone code modifications.
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of the underlying mechanisms.
A previous study in prostate cancer PC-3 cells revealed
that overexpression of MT3 significantly increased cell
proliferation, invasion and tumorigenic activities both
in vitro and in vivo [31]. However, there were no reports
on the role of MT3 in leukemia cells. In this study, we
demonstrated that HL-60 and MV4-11 leukemia cells
overexpressing MT3 inhibited cell proliferation in a dose-
dependent manner. Further analysis by Annexin V assay
revealed that there were a greater proportion of apoptotic
cells in MT3-overexpressing leukemia cells compared to
mock transfected cells. The apoptotic effect of MT3 in
leukemia cells was confirmed by Western blot analysis
which showed that MT3 overexpression led to enhanced
expression of cleaved PARP, a marker of apoptosis. These
findings suggested that MT3 may possess promising anti-
tumor activity in AML cells.
Real-time PCR array analysis is an effective technique
for quantifying the expression of a focused panel of
genes [32,33]. Therefore, in order to explore the under-
lying mechanisms of MT3 antitumor activity, we carried
out a real-time PCR array assay on 370 apoptosis-related
genes in order to identify those genes that were dys-
regulated in AML following MT3 overexpression. The
findings showed that 17 of the genes were significantly up-
regulated and 17 genes were significantly downregulated in
MT3-overexpressing cells relative to control cells. The
gene that was most significantly upregulated was found to
be FOXO1, which belongs to the family of forkhead box
transcription factors. These are downstream targets in the
serine/threonine protein kinase B (PKB)/Akt pathway
which is involved in the regulation of cell proliferation and
survival [34-36]. It has been shown that withdrawal of
growth factors leads to inactivation of the PI3K-Akt path-
way, FOXO1 dephosphorylation at its Akt sites, nuclear
translocation and activation of FOXO target genes [35-37].
FOXO1 plays a central role in initiating apoptosis by
inducing expression of death genes, such as FASL. In
the nucleus, FOXO1 is a key mediator of tumor sup-
pression downstream of PTEN. Exogenous expression
of PTEN induces FOXO1 to relocate to the nucleus, re-
storing its transcriptional activation. In addition, a con-
stitutively active form of FOXO1 that cannot be
phosphorylated by Akt has been found to induce apop-
tosis in PTEN-null cells, indicating that it has the same
effect as reconstitution of PTEN [38]. Our results indi-
cated that FOXO1 is a downstream target of MT3 in
pediatric AML. A study in prostate cancer cells sug-
gested that overexpression of FOXO1 resulted in apop-
tosis via increased expression of TRAIL (TNF-Related
Apoptosis-Inducing Ligand) [39]. However, the mech-
anism and the role of these genes in MT3-induced
apoptosis in AML remain to be elucidated.Conclusions
In this study, we identified epigenetic inactivation of
MT3 in both AML cell lines and pediatric AML samples
via hypermethylation of the MT3 promoter. Our find-
ings also showed that transcriptional overexpression of
MT3 could inhibit proliferation and induce apoptosis in
AML cells. We identified 34 dysregulated apoptosis-
related genes in MT3-overexpressing, including FOXO1.
These results may provide new insights into the mo-
lecular mechanism of MT3-induced apoptosis; how-
ever, further research will be required to determine the
underlying details. Together, our findings suggest that
MT3 may act as a putative tumor suppressor gene in
pediatric AML.
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